San Diego, CA – Aubex Therapeutics Inc., an emerging pharmaceutical company, today proudly announced an exclusive licensing agreement with Georgetown University to accelerate the development of ATX100, a novel LXR agonist targeting solid tumor malignancies. Jeffrey Glazer, Board Member and Interim CEO of Aubex Therapeutics, highlighted the agreement as a strategic step forward in the company's commitment to innovating therapies in immuno-oncology focused on the tumor microenvironment.
Jeffrey Glazer expressed his enthusiasm about the collaboration, saying, "This exclusive licensing agreement with Georgetown University marks a pivotal moment for Aubex Therapeutics. ATX100 has demonstrated early activity in modifying the tumor microenvironment, making it a promising path in immuno-oncology. We are thrilled to work closely with Georgetown’s distinguished researchers to pursue innovative therapies in cancer treatment."
The collaboration focuses on unlocking the full potential of ATX100 in the clinical setting. This innovative therapy targets a wide range of solid tumors, including breast, pancreatic, and lung cancers, utilizing a mechanism designed to reduce fibrosis and enhance immune responses against cancer.
The collaboration between Aubex Therapeutics and Georgetown University is set to drive significant advancements in the treatment of solid tumors, aiming to improve patient outcomes through cutting-edge research and collaboration. Under the leadership of Glazer, Aubex is dedicated to the near term development and completion of IND enabling work of ATX100 to advance toward the clinical stage.
Guided by a team of seasoned scientific founders, Chief Medical Officer, Dr. Moshe Levi, MD and Chief Scientific Officer, Dr. Robert I. Glazer, Ph.D. and led by experienced attorney and entrepreneur, Jeffrey Glazer, Aubex Therapeutics stands at the forefront of developing groundbreaking cancer treatments. The company is committed to innovative solutions that address the complexities of cancer therapy, dedicated to enhancing patient health and innovative advancements in the field of oncology.